Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study)
Woo-Baek Chung,1 Sang-Hyun Ihm,2 Sung-Won Jang,3 Sung-Ho Her,4 Chul Soo Park,5 Jong-Min Lee,6 Kiyuk Chang,1 Doo-Soo Jeon,7 Ki-Dong Yoo,8 Ki-Bae Seung1 1Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of K...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Chung WB [verfasserIn] Ihm SH [verfasserIn] Jang SW [verfasserIn] Her SH [verfasserIn] Park CS [verfasserIn] Lee JM [verfasserIn] Chang K [verfasserIn] Jeon DS [verfasserIn] Yoo KD [verfasserIn] Seung KB [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Drug Design, Development and Therapy - Dove Medical Press, 2008, (2020), Seite 347-360 |
|---|---|
| Übergeordnetes Werk: |
year:2020 ; pages:347-360 |
| Links: |
|---|
| Katalog-ID: |
DOAJ004011139 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ004011139 | ||
| 003 | DE-627 | ||
| 005 | 20230309181603.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)DOAJ004011139 | ||
| 035 | |a (DE-599)DOAJ618dc4eeae68416fab8102190bd2926f | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RM1-950 | |
| 100 | 0 | |a Chung WB |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study) |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Woo-Baek Chung,1 Sang-Hyun Ihm,2 Sung-Won Jang,3 Sung-Ho Her,4 Chul Soo Park,5 Jong-Min Lee,6 Kiyuk Chang,1 Doo-Soo Jeon,7 Ki-Dong Yoo,8 Ki-Bae Seung1 1Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 2Division of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 3Division of Cardiology, Department of Internal Medicine, St. Paul’s Hospital; 4Daejeon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 5Division of Cardiology, Department of Internal Medicine, Yeouido St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 6Division of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 7Division of Cardiology, Department of Internal Medicine, In-Cheon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 8Division of Cardiology, Department of Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Seoul, Republic of KoreaCorrespondence: Sang-Hyun IhmDivision of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 14647, 327, Sosa-ro, Bucheon-si, Gyeonggi-do, Republic of KoreaTel +82-32-340-7027Fax +82-32-340-2669Email heartihmshyahoo.co.krKi-Bae SeungDivision of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 06591, 222, Banpo-daero, Seocho-gu, Seoul, Republic of KoreaTel +82-2-2258-1134Fax +82-2-591-1506Email kbseung@catholic.ac.krPurpose: Head-to-head comparison of the blood pressure (BP) lowering effect of fimasartan versus valsartan, with olmesartan as a reference, on office blood pressure and ambulatory BP.Patients and Methods: Of the 369 randomly assigned patients in this study, 365 hypertensive patients were referred as the full analysis set and divided into 3 groups with a 3:3:1 ratio (fimasartan group: 155, valsartan group: 157, olmesartan group: 53). After the 2-week single-blind placebo run-in period, initial standard doses of 60-mg fimasartan, 80-mg valsartan, and 10-mg olmesartan were administered for 2 weeks, then forcibly up-titrated higher doses (fimasartan 120 mg, valsartan 160 mg, olmesartan 20 mg) were given for 4 weeks. ABP was measured before and after the 6-week treatment. Primary endpoint was reduction of sitting office systolic BP (SiSBP) of fimasartan compared to valsartan after 6 weeks. Secondary endpoints were reduction of sitting office diastolic BP (SiDBP) and 24 hrs, day-time, and night-time mean systolic and diastolic ABP (ASBP, ADBP) after 6 weeks.Results: Patients’ mean age was 58.34+- 7.68 years, and 289 patients were male (79.18%). After the 6-week treatment, SiSBP reduction of fimasartan and valsartan were - 16.26+- 15.07 and - 12.81+- 13.87 (p=0.0298) and SiDBP were - 7.63+- 9.67 and - 5.14+- 8.52 (p=0.0211). Reductions in 24 hrs mean ASBP were - 15.22+- 13.33 and - 9.45+- 12.37 (p=0.0009), and ADBPs were - 8.74+- 7.55 and - 5.98+- 7.85 (p=0.0140). Reductions of night-time ASBPs were - 16.80+- 15.81 and - 10.32+- 14.88 (p=0.0012), and those of night-time ADBPs were - 8.89+- 9.93 and - 5.55+- 9.70 (p=0.0152). Reduction of BP in olmesartan group did not demonstrate significant difference with fimasartan group in all end-points.Conclusion: Fimasartan 120-mg treatment demonstrated superior efficacy in reduction of SiSBP, SiDBP, and 24 hrs ASBP and ADBP compared to valsartan 160 mg. Reduction of night-time ASBP from baseline was largest in fimasartan group, suggesting that fimasartan may be effective for recovering dipping pattern.NCT number: NCT02495324 (Fimasartan Achieving SBP Target (FAST) study).Keywords: 24 hr ambulatory blood pressure monitoring, angiotensin receptor blocker, essential hypertension, antihypertensive | ||
| 650 | 4 | |a 24-hour ambulatory blood pressure monitoring | |
| 650 | 4 | |a angiotensin receptor blocker | |
| 650 | 4 | |a essential hypertension | |
| 650 | 4 | |a antihypertensive | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 700 | 0 | |a Ihm SH |e verfasserin |4 aut | |
| 700 | 0 | |a Jang SW |e verfasserin |4 aut | |
| 700 | 0 | |a Her SH |e verfasserin |4 aut | |
| 700 | 0 | |a Park CS |e verfasserin |4 aut | |
| 700 | 0 | |a Lee JM |e verfasserin |4 aut | |
| 700 | 0 | |a Chang K |e verfasserin |4 aut | |
| 700 | 0 | |a Jeon DS |e verfasserin |4 aut | |
| 700 | 0 | |a Yoo KD |e verfasserin |4 aut | |
| 700 | 0 | |a Seung KB |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Drug Design, Development and Therapy |d Dove Medical Press, 2008 |g (2020), Seite 347-360 |w (DE-627)578533138 |w (DE-600)2451346-5 |x 11778881 |7 nnns |
| 773 | 1 | 8 | |g year:2020 |g pages:347-360 |
| 856 | 4 | 0 | |u https://doaj.org/article/618dc4eeae68416fab8102190bd2926f |z kostenfrei |
| 856 | 4 | 0 | |u https://www.dovepress.com/effect-of-fimasartan-versus-valsartan-and-olmesartan-on-office-and-amb-peer-reviewed-article-DDDT |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1177-8881 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |j 2020 |h 347-360 | ||
| author_variant |
c w cw i s is j s js h s hs p c pc l j lj c k ck j d jd y k yk s k sk |
|---|---|
| matchkey_str |
article:11778881:2020----::fetfiaatnessasraadleatnnfienabltrbodrsuenoenainsihidooeaesetahpresoaadmzdobelnatvcnrlheprlegopocdirtomlie |
| hierarchy_sort_str |
2020 |
| callnumber-subject-code |
RM |
| publishDate |
2020 |
| allfields |
(DE-627)DOAJ004011139 (DE-599)DOAJ618dc4eeae68416fab8102190bd2926f DE-627 ger DE-627 rakwb eng RM1-950 Chung WB verfasserin aut Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Woo-Baek Chung,1 Sang-Hyun Ihm,2 Sung-Won Jang,3 Sung-Ho Her,4 Chul Soo Park,5 Jong-Min Lee,6 Kiyuk Chang,1 Doo-Soo Jeon,7 Ki-Dong Yoo,8 Ki-Bae Seung1 1Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 2Division of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 3Division of Cardiology, Department of Internal Medicine, St. Paul’s Hospital; 4Daejeon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 5Division of Cardiology, Department of Internal Medicine, Yeouido St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 6Division of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 7Division of Cardiology, Department of Internal Medicine, In-Cheon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 8Division of Cardiology, Department of Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Seoul, Republic of KoreaCorrespondence: Sang-Hyun IhmDivision of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 14647, 327, Sosa-ro, Bucheon-si, Gyeonggi-do, Republic of KoreaTel +82-32-340-7027Fax +82-32-340-2669Email heartihmshyahoo.co.krKi-Bae SeungDivision of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 06591, 222, Banpo-daero, Seocho-gu, Seoul, Republic of KoreaTel +82-2-2258-1134Fax +82-2-591-1506Email kbseung@catholic.ac.krPurpose: Head-to-head comparison of the blood pressure (BP) lowering effect of fimasartan versus valsartan, with olmesartan as a reference, on office blood pressure and ambulatory BP.Patients and Methods: Of the 369 randomly assigned patients in this study, 365 hypertensive patients were referred as the full analysis set and divided into 3 groups with a 3:3:1 ratio (fimasartan group: 155, valsartan group: 157, olmesartan group: 53). After the 2-week single-blind placebo run-in period, initial standard doses of 60-mg fimasartan, 80-mg valsartan, and 10-mg olmesartan were administered for 2 weeks, then forcibly up-titrated higher doses (fimasartan 120 mg, valsartan 160 mg, olmesartan 20 mg) were given for 4 weeks. ABP was measured before and after the 6-week treatment. Primary endpoint was reduction of sitting office systolic BP (SiSBP) of fimasartan compared to valsartan after 6 weeks. Secondary endpoints were reduction of sitting office diastolic BP (SiDBP) and 24 hrs, day-time, and night-time mean systolic and diastolic ABP (ASBP, ADBP) after 6 weeks.Results: Patients’ mean age was 58.34+- 7.68 years, and 289 patients were male (79.18%). After the 6-week treatment, SiSBP reduction of fimasartan and valsartan were - 16.26+- 15.07 and - 12.81+- 13.87 (p=0.0298) and SiDBP were - 7.63+- 9.67 and - 5.14+- 8.52 (p=0.0211). Reductions in 24 hrs mean ASBP were - 15.22+- 13.33 and - 9.45+- 12.37 (p=0.0009), and ADBPs were - 8.74+- 7.55 and - 5.98+- 7.85 (p=0.0140). Reductions of night-time ASBPs were - 16.80+- 15.81 and - 10.32+- 14.88 (p=0.0012), and those of night-time ADBPs were - 8.89+- 9.93 and - 5.55+- 9.70 (p=0.0152). Reduction of BP in olmesartan group did not demonstrate significant difference with fimasartan group in all end-points.Conclusion: Fimasartan 120-mg treatment demonstrated superior efficacy in reduction of SiSBP, SiDBP, and 24 hrs ASBP and ADBP compared to valsartan 160 mg. Reduction of night-time ASBP from baseline was largest in fimasartan group, suggesting that fimasartan may be effective for recovering dipping pattern.NCT number: NCT02495324 (Fimasartan Achieving SBP Target (FAST) study).Keywords: 24 hr ambulatory blood pressure monitoring, angiotensin receptor blocker, essential hypertension, antihypertensive 24-hour ambulatory blood pressure monitoring angiotensin receptor blocker essential hypertension antihypertensive Therapeutics. Pharmacology Ihm SH verfasserin aut Jang SW verfasserin aut Her SH verfasserin aut Park CS verfasserin aut Lee JM verfasserin aut Chang K verfasserin aut Jeon DS verfasserin aut Yoo KD verfasserin aut Seung KB verfasserin aut In Drug Design, Development and Therapy Dove Medical Press, 2008 (2020), Seite 347-360 (DE-627)578533138 (DE-600)2451346-5 11778881 nnns year:2020 pages:347-360 https://doaj.org/article/618dc4eeae68416fab8102190bd2926f kostenfrei https://www.dovepress.com/effect-of-fimasartan-versus-valsartan-and-olmesartan-on-office-and-amb-peer-reviewed-article-DDDT kostenfrei https://doaj.org/toc/1177-8881 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 347-360 |
| spelling |
(DE-627)DOAJ004011139 (DE-599)DOAJ618dc4eeae68416fab8102190bd2926f DE-627 ger DE-627 rakwb eng RM1-950 Chung WB verfasserin aut Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Woo-Baek Chung,1 Sang-Hyun Ihm,2 Sung-Won Jang,3 Sung-Ho Her,4 Chul Soo Park,5 Jong-Min Lee,6 Kiyuk Chang,1 Doo-Soo Jeon,7 Ki-Dong Yoo,8 Ki-Bae Seung1 1Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 2Division of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 3Division of Cardiology, Department of Internal Medicine, St. Paul’s Hospital; 4Daejeon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 5Division of Cardiology, Department of Internal Medicine, Yeouido St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 6Division of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 7Division of Cardiology, Department of Internal Medicine, In-Cheon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 8Division of Cardiology, Department of Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Seoul, Republic of KoreaCorrespondence: Sang-Hyun IhmDivision of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 14647, 327, Sosa-ro, Bucheon-si, Gyeonggi-do, Republic of KoreaTel +82-32-340-7027Fax +82-32-340-2669Email heartihmshyahoo.co.krKi-Bae SeungDivision of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 06591, 222, Banpo-daero, Seocho-gu, Seoul, Republic of KoreaTel +82-2-2258-1134Fax +82-2-591-1506Email kbseung@catholic.ac.krPurpose: Head-to-head comparison of the blood pressure (BP) lowering effect of fimasartan versus valsartan, with olmesartan as a reference, on office blood pressure and ambulatory BP.Patients and Methods: Of the 369 randomly assigned patients in this study, 365 hypertensive patients were referred as the full analysis set and divided into 3 groups with a 3:3:1 ratio (fimasartan group: 155, valsartan group: 157, olmesartan group: 53). After the 2-week single-blind placebo run-in period, initial standard doses of 60-mg fimasartan, 80-mg valsartan, and 10-mg olmesartan were administered for 2 weeks, then forcibly up-titrated higher doses (fimasartan 120 mg, valsartan 160 mg, olmesartan 20 mg) were given for 4 weeks. ABP was measured before and after the 6-week treatment. Primary endpoint was reduction of sitting office systolic BP (SiSBP) of fimasartan compared to valsartan after 6 weeks. Secondary endpoints were reduction of sitting office diastolic BP (SiDBP) and 24 hrs, day-time, and night-time mean systolic and diastolic ABP (ASBP, ADBP) after 6 weeks.Results: Patients’ mean age was 58.34+- 7.68 years, and 289 patients were male (79.18%). After the 6-week treatment, SiSBP reduction of fimasartan and valsartan were - 16.26+- 15.07 and - 12.81+- 13.87 (p=0.0298) and SiDBP were - 7.63+- 9.67 and - 5.14+- 8.52 (p=0.0211). Reductions in 24 hrs mean ASBP were - 15.22+- 13.33 and - 9.45+- 12.37 (p=0.0009), and ADBPs were - 8.74+- 7.55 and - 5.98+- 7.85 (p=0.0140). Reductions of night-time ASBPs were - 16.80+- 15.81 and - 10.32+- 14.88 (p=0.0012), and those of night-time ADBPs were - 8.89+- 9.93 and - 5.55+- 9.70 (p=0.0152). Reduction of BP in olmesartan group did not demonstrate significant difference with fimasartan group in all end-points.Conclusion: Fimasartan 120-mg treatment demonstrated superior efficacy in reduction of SiSBP, SiDBP, and 24 hrs ASBP and ADBP compared to valsartan 160 mg. Reduction of night-time ASBP from baseline was largest in fimasartan group, suggesting that fimasartan may be effective for recovering dipping pattern.NCT number: NCT02495324 (Fimasartan Achieving SBP Target (FAST) study).Keywords: 24 hr ambulatory blood pressure monitoring, angiotensin receptor blocker, essential hypertension, antihypertensive 24-hour ambulatory blood pressure monitoring angiotensin receptor blocker essential hypertension antihypertensive Therapeutics. Pharmacology Ihm SH verfasserin aut Jang SW verfasserin aut Her SH verfasserin aut Park CS verfasserin aut Lee JM verfasserin aut Chang K verfasserin aut Jeon DS verfasserin aut Yoo KD verfasserin aut Seung KB verfasserin aut In Drug Design, Development and Therapy Dove Medical Press, 2008 (2020), Seite 347-360 (DE-627)578533138 (DE-600)2451346-5 11778881 nnns year:2020 pages:347-360 https://doaj.org/article/618dc4eeae68416fab8102190bd2926f kostenfrei https://www.dovepress.com/effect-of-fimasartan-versus-valsartan-and-olmesartan-on-office-and-amb-peer-reviewed-article-DDDT kostenfrei https://doaj.org/toc/1177-8881 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 347-360 |
| allfields_unstemmed |
(DE-627)DOAJ004011139 (DE-599)DOAJ618dc4eeae68416fab8102190bd2926f DE-627 ger DE-627 rakwb eng RM1-950 Chung WB verfasserin aut Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Woo-Baek Chung,1 Sang-Hyun Ihm,2 Sung-Won Jang,3 Sung-Ho Her,4 Chul Soo Park,5 Jong-Min Lee,6 Kiyuk Chang,1 Doo-Soo Jeon,7 Ki-Dong Yoo,8 Ki-Bae Seung1 1Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 2Division of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 3Division of Cardiology, Department of Internal Medicine, St. Paul’s Hospital; 4Daejeon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 5Division of Cardiology, Department of Internal Medicine, Yeouido St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 6Division of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 7Division of Cardiology, Department of Internal Medicine, In-Cheon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 8Division of Cardiology, Department of Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Seoul, Republic of KoreaCorrespondence: Sang-Hyun IhmDivision of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 14647, 327, Sosa-ro, Bucheon-si, Gyeonggi-do, Republic of KoreaTel +82-32-340-7027Fax +82-32-340-2669Email heartihmshyahoo.co.krKi-Bae SeungDivision of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 06591, 222, Banpo-daero, Seocho-gu, Seoul, Republic of KoreaTel +82-2-2258-1134Fax +82-2-591-1506Email kbseung@catholic.ac.krPurpose: Head-to-head comparison of the blood pressure (BP) lowering effect of fimasartan versus valsartan, with olmesartan as a reference, on office blood pressure and ambulatory BP.Patients and Methods: Of the 369 randomly assigned patients in this study, 365 hypertensive patients were referred as the full analysis set and divided into 3 groups with a 3:3:1 ratio (fimasartan group: 155, valsartan group: 157, olmesartan group: 53). After the 2-week single-blind placebo run-in period, initial standard doses of 60-mg fimasartan, 80-mg valsartan, and 10-mg olmesartan were administered for 2 weeks, then forcibly up-titrated higher doses (fimasartan 120 mg, valsartan 160 mg, olmesartan 20 mg) were given for 4 weeks. ABP was measured before and after the 6-week treatment. Primary endpoint was reduction of sitting office systolic BP (SiSBP) of fimasartan compared to valsartan after 6 weeks. Secondary endpoints were reduction of sitting office diastolic BP (SiDBP) and 24 hrs, day-time, and night-time mean systolic and diastolic ABP (ASBP, ADBP) after 6 weeks.Results: Patients’ mean age was 58.34+- 7.68 years, and 289 patients were male (79.18%). After the 6-week treatment, SiSBP reduction of fimasartan and valsartan were - 16.26+- 15.07 and - 12.81+- 13.87 (p=0.0298) and SiDBP were - 7.63+- 9.67 and - 5.14+- 8.52 (p=0.0211). Reductions in 24 hrs mean ASBP were - 15.22+- 13.33 and - 9.45+- 12.37 (p=0.0009), and ADBPs were - 8.74+- 7.55 and - 5.98+- 7.85 (p=0.0140). Reductions of night-time ASBPs were - 16.80+- 15.81 and - 10.32+- 14.88 (p=0.0012), and those of night-time ADBPs were - 8.89+- 9.93 and - 5.55+- 9.70 (p=0.0152). Reduction of BP in olmesartan group did not demonstrate significant difference with fimasartan group in all end-points.Conclusion: Fimasartan 120-mg treatment demonstrated superior efficacy in reduction of SiSBP, SiDBP, and 24 hrs ASBP and ADBP compared to valsartan 160 mg. Reduction of night-time ASBP from baseline was largest in fimasartan group, suggesting that fimasartan may be effective for recovering dipping pattern.NCT number: NCT02495324 (Fimasartan Achieving SBP Target (FAST) study).Keywords: 24 hr ambulatory blood pressure monitoring, angiotensin receptor blocker, essential hypertension, antihypertensive 24-hour ambulatory blood pressure monitoring angiotensin receptor blocker essential hypertension antihypertensive Therapeutics. Pharmacology Ihm SH verfasserin aut Jang SW verfasserin aut Her SH verfasserin aut Park CS verfasserin aut Lee JM verfasserin aut Chang K verfasserin aut Jeon DS verfasserin aut Yoo KD verfasserin aut Seung KB verfasserin aut In Drug Design, Development and Therapy Dove Medical Press, 2008 (2020), Seite 347-360 (DE-627)578533138 (DE-600)2451346-5 11778881 nnns year:2020 pages:347-360 https://doaj.org/article/618dc4eeae68416fab8102190bd2926f kostenfrei https://www.dovepress.com/effect-of-fimasartan-versus-valsartan-and-olmesartan-on-office-and-amb-peer-reviewed-article-DDDT kostenfrei https://doaj.org/toc/1177-8881 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 347-360 |
| allfieldsGer |
(DE-627)DOAJ004011139 (DE-599)DOAJ618dc4eeae68416fab8102190bd2926f DE-627 ger DE-627 rakwb eng RM1-950 Chung WB verfasserin aut Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Woo-Baek Chung,1 Sang-Hyun Ihm,2 Sung-Won Jang,3 Sung-Ho Her,4 Chul Soo Park,5 Jong-Min Lee,6 Kiyuk Chang,1 Doo-Soo Jeon,7 Ki-Dong Yoo,8 Ki-Bae Seung1 1Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 2Division of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 3Division of Cardiology, Department of Internal Medicine, St. Paul’s Hospital; 4Daejeon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 5Division of Cardiology, Department of Internal Medicine, Yeouido St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 6Division of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 7Division of Cardiology, Department of Internal Medicine, In-Cheon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 8Division of Cardiology, Department of Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Seoul, Republic of KoreaCorrespondence: Sang-Hyun IhmDivision of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 14647, 327, Sosa-ro, Bucheon-si, Gyeonggi-do, Republic of KoreaTel +82-32-340-7027Fax +82-32-340-2669Email heartihmshyahoo.co.krKi-Bae SeungDivision of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 06591, 222, Banpo-daero, Seocho-gu, Seoul, Republic of KoreaTel +82-2-2258-1134Fax +82-2-591-1506Email kbseung@catholic.ac.krPurpose: Head-to-head comparison of the blood pressure (BP) lowering effect of fimasartan versus valsartan, with olmesartan as a reference, on office blood pressure and ambulatory BP.Patients and Methods: Of the 369 randomly assigned patients in this study, 365 hypertensive patients were referred as the full analysis set and divided into 3 groups with a 3:3:1 ratio (fimasartan group: 155, valsartan group: 157, olmesartan group: 53). After the 2-week single-blind placebo run-in period, initial standard doses of 60-mg fimasartan, 80-mg valsartan, and 10-mg olmesartan were administered for 2 weeks, then forcibly up-titrated higher doses (fimasartan 120 mg, valsartan 160 mg, olmesartan 20 mg) were given for 4 weeks. ABP was measured before and after the 6-week treatment. Primary endpoint was reduction of sitting office systolic BP (SiSBP) of fimasartan compared to valsartan after 6 weeks. Secondary endpoints were reduction of sitting office diastolic BP (SiDBP) and 24 hrs, day-time, and night-time mean systolic and diastolic ABP (ASBP, ADBP) after 6 weeks.Results: Patients’ mean age was 58.34+- 7.68 years, and 289 patients were male (79.18%). After the 6-week treatment, SiSBP reduction of fimasartan and valsartan were - 16.26+- 15.07 and - 12.81+- 13.87 (p=0.0298) and SiDBP were - 7.63+- 9.67 and - 5.14+- 8.52 (p=0.0211). Reductions in 24 hrs mean ASBP were - 15.22+- 13.33 and - 9.45+- 12.37 (p=0.0009), and ADBPs were - 8.74+- 7.55 and - 5.98+- 7.85 (p=0.0140). Reductions of night-time ASBPs were - 16.80+- 15.81 and - 10.32+- 14.88 (p=0.0012), and those of night-time ADBPs were - 8.89+- 9.93 and - 5.55+- 9.70 (p=0.0152). Reduction of BP in olmesartan group did not demonstrate significant difference with fimasartan group in all end-points.Conclusion: Fimasartan 120-mg treatment demonstrated superior efficacy in reduction of SiSBP, SiDBP, and 24 hrs ASBP and ADBP compared to valsartan 160 mg. Reduction of night-time ASBP from baseline was largest in fimasartan group, suggesting that fimasartan may be effective for recovering dipping pattern.NCT number: NCT02495324 (Fimasartan Achieving SBP Target (FAST) study).Keywords: 24 hr ambulatory blood pressure monitoring, angiotensin receptor blocker, essential hypertension, antihypertensive 24-hour ambulatory blood pressure monitoring angiotensin receptor blocker essential hypertension antihypertensive Therapeutics. Pharmacology Ihm SH verfasserin aut Jang SW verfasserin aut Her SH verfasserin aut Park CS verfasserin aut Lee JM verfasserin aut Chang K verfasserin aut Jeon DS verfasserin aut Yoo KD verfasserin aut Seung KB verfasserin aut In Drug Design, Development and Therapy Dove Medical Press, 2008 (2020), Seite 347-360 (DE-627)578533138 (DE-600)2451346-5 11778881 nnns year:2020 pages:347-360 https://doaj.org/article/618dc4eeae68416fab8102190bd2926f kostenfrei https://www.dovepress.com/effect-of-fimasartan-versus-valsartan-and-olmesartan-on-office-and-amb-peer-reviewed-article-DDDT kostenfrei https://doaj.org/toc/1177-8881 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 347-360 |
| allfieldsSound |
(DE-627)DOAJ004011139 (DE-599)DOAJ618dc4eeae68416fab8102190bd2926f DE-627 ger DE-627 rakwb eng RM1-950 Chung WB verfasserin aut Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Woo-Baek Chung,1 Sang-Hyun Ihm,2 Sung-Won Jang,3 Sung-Ho Her,4 Chul Soo Park,5 Jong-Min Lee,6 Kiyuk Chang,1 Doo-Soo Jeon,7 Ki-Dong Yoo,8 Ki-Bae Seung1 1Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 2Division of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 3Division of Cardiology, Department of Internal Medicine, St. Paul’s Hospital; 4Daejeon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 5Division of Cardiology, Department of Internal Medicine, Yeouido St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 6Division of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 7Division of Cardiology, Department of Internal Medicine, In-Cheon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 8Division of Cardiology, Department of Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Seoul, Republic of KoreaCorrespondence: Sang-Hyun IhmDivision of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 14647, 327, Sosa-ro, Bucheon-si, Gyeonggi-do, Republic of KoreaTel +82-32-340-7027Fax +82-32-340-2669Email heartihmshyahoo.co.krKi-Bae SeungDivision of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 06591, 222, Banpo-daero, Seocho-gu, Seoul, Republic of KoreaTel +82-2-2258-1134Fax +82-2-591-1506Email kbseung@catholic.ac.krPurpose: Head-to-head comparison of the blood pressure (BP) lowering effect of fimasartan versus valsartan, with olmesartan as a reference, on office blood pressure and ambulatory BP.Patients and Methods: Of the 369 randomly assigned patients in this study, 365 hypertensive patients were referred as the full analysis set and divided into 3 groups with a 3:3:1 ratio (fimasartan group: 155, valsartan group: 157, olmesartan group: 53). After the 2-week single-blind placebo run-in period, initial standard doses of 60-mg fimasartan, 80-mg valsartan, and 10-mg olmesartan were administered for 2 weeks, then forcibly up-titrated higher doses (fimasartan 120 mg, valsartan 160 mg, olmesartan 20 mg) were given for 4 weeks. ABP was measured before and after the 6-week treatment. Primary endpoint was reduction of sitting office systolic BP (SiSBP) of fimasartan compared to valsartan after 6 weeks. Secondary endpoints were reduction of sitting office diastolic BP (SiDBP) and 24 hrs, day-time, and night-time mean systolic and diastolic ABP (ASBP, ADBP) after 6 weeks.Results: Patients’ mean age was 58.34+- 7.68 years, and 289 patients were male (79.18%). After the 6-week treatment, SiSBP reduction of fimasartan and valsartan were - 16.26+- 15.07 and - 12.81+- 13.87 (p=0.0298) and SiDBP were - 7.63+- 9.67 and - 5.14+- 8.52 (p=0.0211). Reductions in 24 hrs mean ASBP were - 15.22+- 13.33 and - 9.45+- 12.37 (p=0.0009), and ADBPs were - 8.74+- 7.55 and - 5.98+- 7.85 (p=0.0140). Reductions of night-time ASBPs were - 16.80+- 15.81 and - 10.32+- 14.88 (p=0.0012), and those of night-time ADBPs were - 8.89+- 9.93 and - 5.55+- 9.70 (p=0.0152). Reduction of BP in olmesartan group did not demonstrate significant difference with fimasartan group in all end-points.Conclusion: Fimasartan 120-mg treatment demonstrated superior efficacy in reduction of SiSBP, SiDBP, and 24 hrs ASBP and ADBP compared to valsartan 160 mg. Reduction of night-time ASBP from baseline was largest in fimasartan group, suggesting that fimasartan may be effective for recovering dipping pattern.NCT number: NCT02495324 (Fimasartan Achieving SBP Target (FAST) study).Keywords: 24 hr ambulatory blood pressure monitoring, angiotensin receptor blocker, essential hypertension, antihypertensive 24-hour ambulatory blood pressure monitoring angiotensin receptor blocker essential hypertension antihypertensive Therapeutics. Pharmacology Ihm SH verfasserin aut Jang SW verfasserin aut Her SH verfasserin aut Park CS verfasserin aut Lee JM verfasserin aut Chang K verfasserin aut Jeon DS verfasserin aut Yoo KD verfasserin aut Seung KB verfasserin aut In Drug Design, Development and Therapy Dove Medical Press, 2008 (2020), Seite 347-360 (DE-627)578533138 (DE-600)2451346-5 11778881 nnns year:2020 pages:347-360 https://doaj.org/article/618dc4eeae68416fab8102190bd2926f kostenfrei https://www.dovepress.com/effect-of-fimasartan-versus-valsartan-and-olmesartan-on-office-and-amb-peer-reviewed-article-DDDT kostenfrei https://doaj.org/toc/1177-8881 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 347-360 |
| language |
English |
| source |
In Drug Design, Development and Therapy (2020), Seite 347-360 year:2020 pages:347-360 |
| sourceStr |
In Drug Design, Development and Therapy (2020), Seite 347-360 year:2020 pages:347-360 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
24-hour ambulatory blood pressure monitoring angiotensin receptor blocker essential hypertension antihypertensive Therapeutics. Pharmacology |
| isfreeaccess_bool |
true |
| container_title |
Drug Design, Development and Therapy |
| authorswithroles_txt_mv |
Chung WB @@aut@@ Ihm SH @@aut@@ Jang SW @@aut@@ Her SH @@aut@@ Park CS @@aut@@ Lee JM @@aut@@ Chang K @@aut@@ Jeon DS @@aut@@ Yoo KD @@aut@@ Seung KB @@aut@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
578533138 |
| id |
DOAJ004011139 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ004011139</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309181603.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ004011139</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ618dc4eeae68416fab8102190bd2926f</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Chung WB</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Woo-Baek Chung,1 Sang-Hyun Ihm,2 Sung-Won Jang,3 Sung-Ho Her,4 Chul Soo Park,5 Jong-Min Lee,6 Kiyuk Chang,1 Doo-Soo Jeon,7 Ki-Dong Yoo,8 Ki-Bae Seung1 1Division of Cardiology, Department of Internal Medicine, Seoul St. Mary&rsquo;s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 2Division of Cardiology, Department of Internal Medicine, Bucheon St. Mary&rsquo;s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 3Division of Cardiology, Department of Internal Medicine, St. Paul&rsquo;s Hospital; 4Daejeon St. Mary&rsquo;s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 5Division of Cardiology, Department of Internal Medicine, Yeouido St. Mary&rsquo;s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 6Division of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary&rsquo;s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 7Division of Cardiology, Department of Internal Medicine, In-Cheon St. Mary&rsquo;s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 8Division of Cardiology, Department of Internal Medicine, St. Vincent&rsquo;s Hospital, The Catholic University of Korea, Seoul, Republic of KoreaCorrespondence: Sang-Hyun IhmDivision of Cardiology, Department of Internal Medicine, Bucheon St. Mary&rsquo;s Hospital, College of Medicine, The Catholic University of Korea, 14647, 327, Sosa-ro, Bucheon-si, Gyeonggi-do, Republic of KoreaTel +82-32-340-7027Fax +82-32-340-2669Email heartihmshyahoo.co.krKi-Bae SeungDivision of Cardiology, Department of Internal Medicine, Seoul St. Mary&rsquo;s Hospital, College of Medicine, The Catholic University of Korea, 06591, 222, Banpo-daero, Seocho-gu, Seoul, Republic of KoreaTel +82-2-2258-1134Fax +82-2-591-1506Email kbseung@catholic.ac.krPurpose: Head-to-head comparison of the blood pressure (BP) lowering effect of fimasartan versus valsartan, with olmesartan as a reference, on office blood pressure and ambulatory BP.Patients and Methods: Of the 369 randomly assigned patients in this study, 365 hypertensive patients were referred as the full analysis set and divided into 3 groups with a 3:3:1 ratio (fimasartan group: 155, valsartan group: 157, olmesartan group: 53). After the 2-week single-blind placebo run-in period, initial standard doses of 60-mg fimasartan, 80-mg valsartan, and 10-mg olmesartan were administered for 2 weeks, then forcibly up-titrated higher doses (fimasartan 120 mg, valsartan 160 mg, olmesartan 20 mg) were given for 4 weeks. ABP was measured before and after the 6-week treatment. Primary endpoint was reduction of sitting office systolic BP (SiSBP) of fimasartan compared to valsartan after 6 weeks. Secondary endpoints were reduction of sitting office diastolic BP (SiDBP) and 24 hrs, day-time, and night-time mean systolic and diastolic ABP (ASBP, ADBP) after 6 weeks.Results: Patients&rsquo; mean age was 58.34+- 7.68 years, and 289 patients were male (79.18%). After the 6-week treatment, SiSBP reduction of fimasartan and valsartan were - 16.26+- 15.07 and - 12.81+- 13.87 (p=0.0298) and SiDBP were - 7.63+- 9.67 and - 5.14+- 8.52 (p=0.0211). Reductions in 24 hrs mean ASBP were - 15.22+- 13.33 and - 9.45+- 12.37 (p=0.0009), and ADBPs were - 8.74+- 7.55 and - 5.98+- 7.85 (p=0.0140). Reductions of night-time ASBPs were - 16.80+- 15.81 and - 10.32+- 14.88 (p=0.0012), and those of night-time ADBPs were - 8.89+- 9.93 and - 5.55+- 9.70 (p=0.0152). Reduction of BP in olmesartan group did not demonstrate significant difference with fimasartan group in all end-points.Conclusion: Fimasartan 120-mg treatment demonstrated superior efficacy in reduction of SiSBP, SiDBP, and 24 hrs ASBP and ADBP compared to valsartan 160 mg. Reduction of night-time ASBP from baseline was largest in fimasartan group, suggesting that fimasartan may be effective for recovering dipping pattern.NCT number: NCT02495324 (Fimasartan Achieving SBP Target (FAST) study).Keywords: 24 hr ambulatory blood pressure monitoring, angiotensin receptor blocker, essential hypertension, antihypertensive</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">24-hour ambulatory blood pressure monitoring</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">angiotensin receptor blocker</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">essential hypertension</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antihypertensive</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ihm SH</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jang SW</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Her SH</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Park CS</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lee JM</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chang K</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jeon DS</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yoo KD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Seung KB</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Drug Design, Development and Therapy</subfield><subfield code="d">Dove Medical Press, 2008</subfield><subfield code="g">(2020), Seite 347-360</subfield><subfield code="w">(DE-627)578533138</subfield><subfield code="w">(DE-600)2451346-5</subfield><subfield code="x">11778881</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2020</subfield><subfield code="g">pages:347-360</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/618dc4eeae68416fab8102190bd2926f</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/effect-of-fimasartan-versus-valsartan-and-olmesartan-on-office-and-amb-peer-reviewed-article-DDDT</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1177-8881</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2020</subfield><subfield code="h">347-360</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Chung WB |
| spellingShingle |
Chung WB misc RM1-950 misc 24-hour ambulatory blood pressure monitoring misc angiotensin receptor blocker misc essential hypertension misc antihypertensive misc Therapeutics. Pharmacology Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study) |
| authorStr |
Chung WB |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)578533138 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RM1-950 |
| illustrated |
Not Illustrated |
| issn |
11778881 |
| topic_title |
RM1-950 Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study) 24-hour ambulatory blood pressure monitoring angiotensin receptor blocker essential hypertension antihypertensive |
| topic |
misc RM1-950 misc 24-hour ambulatory blood pressure monitoring misc angiotensin receptor blocker misc essential hypertension misc antihypertensive misc Therapeutics. Pharmacology |
| topic_unstemmed |
misc RM1-950 misc 24-hour ambulatory blood pressure monitoring misc angiotensin receptor blocker misc essential hypertension misc antihypertensive misc Therapeutics. Pharmacology |
| topic_browse |
misc RM1-950 misc 24-hour ambulatory blood pressure monitoring misc angiotensin receptor blocker misc essential hypertension misc antihypertensive misc Therapeutics. Pharmacology |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Drug Design, Development and Therapy |
| hierarchy_parent_id |
578533138 |
| hierarchy_top_title |
Drug Design, Development and Therapy |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)578533138 (DE-600)2451346-5 |
| title |
Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study) |
| ctrlnum |
(DE-627)DOAJ004011139 (DE-599)DOAJ618dc4eeae68416fab8102190bd2926f |
| title_full |
Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study) |
| author_sort |
Chung WB |
| journal |
Drug Design, Development and Therapy |
| journalStr |
Drug Design, Development and Therapy |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
txt |
| container_start_page |
347 |
| author_browse |
Chung WB Ihm SH Jang SW Her SH Park CS Lee JM Chang K Jeon DS Yoo KD Seung KB |
| class |
RM1-950 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Chung WB |
| author2-role |
verfasserin |
| title_sort |
effect of fimasartan versus valsartan and olmesartan on office and ambulatory blood pressure in korean patients with mild-to-moderate essential hypertension: a randomized, double-blind, active control, three-parallel group, forced titration, multicenter, phase iv study (fimasartan achieving systolic blood pressure target (fast) study) |
| callnumber |
RM1-950 |
| title_auth |
Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study) |
| abstract |
Woo-Baek Chung,1 Sang-Hyun Ihm,2 Sung-Won Jang,3 Sung-Ho Her,4 Chul Soo Park,5 Jong-Min Lee,6 Kiyuk Chang,1 Doo-Soo Jeon,7 Ki-Dong Yoo,8 Ki-Bae Seung1 1Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 2Division of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 3Division of Cardiology, Department of Internal Medicine, St. Paul’s Hospital; 4Daejeon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 5Division of Cardiology, Department of Internal Medicine, Yeouido St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 6Division of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 7Division of Cardiology, Department of Internal Medicine, In-Cheon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 8Division of Cardiology, Department of Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Seoul, Republic of KoreaCorrespondence: Sang-Hyun IhmDivision of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 14647, 327, Sosa-ro, Bucheon-si, Gyeonggi-do, Republic of KoreaTel +82-32-340-7027Fax +82-32-340-2669Email heartihmshyahoo.co.krKi-Bae SeungDivision of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 06591, 222, Banpo-daero, Seocho-gu, Seoul, Republic of KoreaTel +82-2-2258-1134Fax +82-2-591-1506Email kbseung@catholic.ac.krPurpose: Head-to-head comparison of the blood pressure (BP) lowering effect of fimasartan versus valsartan, with olmesartan as a reference, on office blood pressure and ambulatory BP.Patients and Methods: Of the 369 randomly assigned patients in this study, 365 hypertensive patients were referred as the full analysis set and divided into 3 groups with a 3:3:1 ratio (fimasartan group: 155, valsartan group: 157, olmesartan group: 53). After the 2-week single-blind placebo run-in period, initial standard doses of 60-mg fimasartan, 80-mg valsartan, and 10-mg olmesartan were administered for 2 weeks, then forcibly up-titrated higher doses (fimasartan 120 mg, valsartan 160 mg, olmesartan 20 mg) were given for 4 weeks. ABP was measured before and after the 6-week treatment. Primary endpoint was reduction of sitting office systolic BP (SiSBP) of fimasartan compared to valsartan after 6 weeks. Secondary endpoints were reduction of sitting office diastolic BP (SiDBP) and 24 hrs, day-time, and night-time mean systolic and diastolic ABP (ASBP, ADBP) after 6 weeks.Results: Patients’ mean age was 58.34+- 7.68 years, and 289 patients were male (79.18%). After the 6-week treatment, SiSBP reduction of fimasartan and valsartan were - 16.26+- 15.07 and - 12.81+- 13.87 (p=0.0298) and SiDBP were - 7.63+- 9.67 and - 5.14+- 8.52 (p=0.0211). Reductions in 24 hrs mean ASBP were - 15.22+- 13.33 and - 9.45+- 12.37 (p=0.0009), and ADBPs were - 8.74+- 7.55 and - 5.98+- 7.85 (p=0.0140). Reductions of night-time ASBPs were - 16.80+- 15.81 and - 10.32+- 14.88 (p=0.0012), and those of night-time ADBPs were - 8.89+- 9.93 and - 5.55+- 9.70 (p=0.0152). Reduction of BP in olmesartan group did not demonstrate significant difference with fimasartan group in all end-points.Conclusion: Fimasartan 120-mg treatment demonstrated superior efficacy in reduction of SiSBP, SiDBP, and 24 hrs ASBP and ADBP compared to valsartan 160 mg. Reduction of night-time ASBP from baseline was largest in fimasartan group, suggesting that fimasartan may be effective for recovering dipping pattern.NCT number: NCT02495324 (Fimasartan Achieving SBP Target (FAST) study).Keywords: 24 hr ambulatory blood pressure monitoring, angiotensin receptor blocker, essential hypertension, antihypertensive |
| abstractGer |
Woo-Baek Chung,1 Sang-Hyun Ihm,2 Sung-Won Jang,3 Sung-Ho Her,4 Chul Soo Park,5 Jong-Min Lee,6 Kiyuk Chang,1 Doo-Soo Jeon,7 Ki-Dong Yoo,8 Ki-Bae Seung1 1Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 2Division of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 3Division of Cardiology, Department of Internal Medicine, St. Paul’s Hospital; 4Daejeon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 5Division of Cardiology, Department of Internal Medicine, Yeouido St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 6Division of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 7Division of Cardiology, Department of Internal Medicine, In-Cheon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 8Division of Cardiology, Department of Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Seoul, Republic of KoreaCorrespondence: Sang-Hyun IhmDivision of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 14647, 327, Sosa-ro, Bucheon-si, Gyeonggi-do, Republic of KoreaTel +82-32-340-7027Fax +82-32-340-2669Email heartihmshyahoo.co.krKi-Bae SeungDivision of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 06591, 222, Banpo-daero, Seocho-gu, Seoul, Republic of KoreaTel +82-2-2258-1134Fax +82-2-591-1506Email kbseung@catholic.ac.krPurpose: Head-to-head comparison of the blood pressure (BP) lowering effect of fimasartan versus valsartan, with olmesartan as a reference, on office blood pressure and ambulatory BP.Patients and Methods: Of the 369 randomly assigned patients in this study, 365 hypertensive patients were referred as the full analysis set and divided into 3 groups with a 3:3:1 ratio (fimasartan group: 155, valsartan group: 157, olmesartan group: 53). After the 2-week single-blind placebo run-in period, initial standard doses of 60-mg fimasartan, 80-mg valsartan, and 10-mg olmesartan were administered for 2 weeks, then forcibly up-titrated higher doses (fimasartan 120 mg, valsartan 160 mg, olmesartan 20 mg) were given for 4 weeks. ABP was measured before and after the 6-week treatment. Primary endpoint was reduction of sitting office systolic BP (SiSBP) of fimasartan compared to valsartan after 6 weeks. Secondary endpoints were reduction of sitting office diastolic BP (SiDBP) and 24 hrs, day-time, and night-time mean systolic and diastolic ABP (ASBP, ADBP) after 6 weeks.Results: Patients’ mean age was 58.34+- 7.68 years, and 289 patients were male (79.18%). After the 6-week treatment, SiSBP reduction of fimasartan and valsartan were - 16.26+- 15.07 and - 12.81+- 13.87 (p=0.0298) and SiDBP were - 7.63+- 9.67 and - 5.14+- 8.52 (p=0.0211). Reductions in 24 hrs mean ASBP were - 15.22+- 13.33 and - 9.45+- 12.37 (p=0.0009), and ADBPs were - 8.74+- 7.55 and - 5.98+- 7.85 (p=0.0140). Reductions of night-time ASBPs were - 16.80+- 15.81 and - 10.32+- 14.88 (p=0.0012), and those of night-time ADBPs were - 8.89+- 9.93 and - 5.55+- 9.70 (p=0.0152). Reduction of BP in olmesartan group did not demonstrate significant difference with fimasartan group in all end-points.Conclusion: Fimasartan 120-mg treatment demonstrated superior efficacy in reduction of SiSBP, SiDBP, and 24 hrs ASBP and ADBP compared to valsartan 160 mg. Reduction of night-time ASBP from baseline was largest in fimasartan group, suggesting that fimasartan may be effective for recovering dipping pattern.NCT number: NCT02495324 (Fimasartan Achieving SBP Target (FAST) study).Keywords: 24 hr ambulatory blood pressure monitoring, angiotensin receptor blocker, essential hypertension, antihypertensive |
| abstract_unstemmed |
Woo-Baek Chung,1 Sang-Hyun Ihm,2 Sung-Won Jang,3 Sung-Ho Her,4 Chul Soo Park,5 Jong-Min Lee,6 Kiyuk Chang,1 Doo-Soo Jeon,7 Ki-Dong Yoo,8 Ki-Bae Seung1 1Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 2Division of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 3Division of Cardiology, Department of Internal Medicine, St. Paul’s Hospital; 4Daejeon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 5Division of Cardiology, Department of Internal Medicine, Yeouido St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 6Division of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 7Division of Cardiology, Department of Internal Medicine, In-Cheon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 8Division of Cardiology, Department of Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Seoul, Republic of KoreaCorrespondence: Sang-Hyun IhmDivision of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 14647, 327, Sosa-ro, Bucheon-si, Gyeonggi-do, Republic of KoreaTel +82-32-340-7027Fax +82-32-340-2669Email heartihmshyahoo.co.krKi-Bae SeungDivision of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 06591, 222, Banpo-daero, Seocho-gu, Seoul, Republic of KoreaTel +82-2-2258-1134Fax +82-2-591-1506Email kbseung@catholic.ac.krPurpose: Head-to-head comparison of the blood pressure (BP) lowering effect of fimasartan versus valsartan, with olmesartan as a reference, on office blood pressure and ambulatory BP.Patients and Methods: Of the 369 randomly assigned patients in this study, 365 hypertensive patients were referred as the full analysis set and divided into 3 groups with a 3:3:1 ratio (fimasartan group: 155, valsartan group: 157, olmesartan group: 53). After the 2-week single-blind placebo run-in period, initial standard doses of 60-mg fimasartan, 80-mg valsartan, and 10-mg olmesartan were administered for 2 weeks, then forcibly up-titrated higher doses (fimasartan 120 mg, valsartan 160 mg, olmesartan 20 mg) were given for 4 weeks. ABP was measured before and after the 6-week treatment. Primary endpoint was reduction of sitting office systolic BP (SiSBP) of fimasartan compared to valsartan after 6 weeks. Secondary endpoints were reduction of sitting office diastolic BP (SiDBP) and 24 hrs, day-time, and night-time mean systolic and diastolic ABP (ASBP, ADBP) after 6 weeks.Results: Patients’ mean age was 58.34+- 7.68 years, and 289 patients were male (79.18%). After the 6-week treatment, SiSBP reduction of fimasartan and valsartan were - 16.26+- 15.07 and - 12.81+- 13.87 (p=0.0298) and SiDBP were - 7.63+- 9.67 and - 5.14+- 8.52 (p=0.0211). Reductions in 24 hrs mean ASBP were - 15.22+- 13.33 and - 9.45+- 12.37 (p=0.0009), and ADBPs were - 8.74+- 7.55 and - 5.98+- 7.85 (p=0.0140). Reductions of night-time ASBPs were - 16.80+- 15.81 and - 10.32+- 14.88 (p=0.0012), and those of night-time ADBPs were - 8.89+- 9.93 and - 5.55+- 9.70 (p=0.0152). Reduction of BP in olmesartan group did not demonstrate significant difference with fimasartan group in all end-points.Conclusion: Fimasartan 120-mg treatment demonstrated superior efficacy in reduction of SiSBP, SiDBP, and 24 hrs ASBP and ADBP compared to valsartan 160 mg. Reduction of night-time ASBP from baseline was largest in fimasartan group, suggesting that fimasartan may be effective for recovering dipping pattern.NCT number: NCT02495324 (Fimasartan Achieving SBP Target (FAST) study).Keywords: 24 hr ambulatory blood pressure monitoring, angiotensin receptor blocker, essential hypertension, antihypertensive |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
| title_short |
Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study) |
| url |
https://doaj.org/article/618dc4eeae68416fab8102190bd2926f https://www.dovepress.com/effect-of-fimasartan-versus-valsartan-and-olmesartan-on-office-and-amb-peer-reviewed-article-DDDT https://doaj.org/toc/1177-8881 |
| remote_bool |
true |
| author2 |
Ihm SH Jang SW Her SH Park CS Lee JM Chang K Jeon DS Yoo KD Seung KB |
| author2Str |
Ihm SH Jang SW Her SH Park CS Lee JM Chang K Jeon DS Yoo KD Seung KB |
| ppnlink |
578533138 |
| callnumber-subject |
RM - Therapeutics and Pharmacology |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| callnumber-a |
RM1-950 |
| up_date |
2024-07-03T21:27:48.238Z |
| _version_ |
1803594831748923392 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ004011139</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309181603.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ004011139</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ618dc4eeae68416fab8102190bd2926f</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Chung WB</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Woo-Baek Chung,1 Sang-Hyun Ihm,2 Sung-Won Jang,3 Sung-Ho Her,4 Chul Soo Park,5 Jong-Min Lee,6 Kiyuk Chang,1 Doo-Soo Jeon,7 Ki-Dong Yoo,8 Ki-Bae Seung1 1Division of Cardiology, Department of Internal Medicine, Seoul St. Mary&rsquo;s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 2Division of Cardiology, Department of Internal Medicine, Bucheon St. Mary&rsquo;s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 3Division of Cardiology, Department of Internal Medicine, St. Paul&rsquo;s Hospital; 4Daejeon St. Mary&rsquo;s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 5Division of Cardiology, Department of Internal Medicine, Yeouido St. Mary&rsquo;s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 6Division of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary&rsquo;s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 7Division of Cardiology, Department of Internal Medicine, In-Cheon St. Mary&rsquo;s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; 8Division of Cardiology, Department of Internal Medicine, St. Vincent&rsquo;s Hospital, The Catholic University of Korea, Seoul, Republic of KoreaCorrespondence: Sang-Hyun IhmDivision of Cardiology, Department of Internal Medicine, Bucheon St. Mary&rsquo;s Hospital, College of Medicine, The Catholic University of Korea, 14647, 327, Sosa-ro, Bucheon-si, Gyeonggi-do, Republic of KoreaTel +82-32-340-7027Fax +82-32-340-2669Email heartihmshyahoo.co.krKi-Bae SeungDivision of Cardiology, Department of Internal Medicine, Seoul St. Mary&rsquo;s Hospital, College of Medicine, The Catholic University of Korea, 06591, 222, Banpo-daero, Seocho-gu, Seoul, Republic of KoreaTel +82-2-2258-1134Fax +82-2-591-1506Email kbseung@catholic.ac.krPurpose: Head-to-head comparison of the blood pressure (BP) lowering effect of fimasartan versus valsartan, with olmesartan as a reference, on office blood pressure and ambulatory BP.Patients and Methods: Of the 369 randomly assigned patients in this study, 365 hypertensive patients were referred as the full analysis set and divided into 3 groups with a 3:3:1 ratio (fimasartan group: 155, valsartan group: 157, olmesartan group: 53). After the 2-week single-blind placebo run-in period, initial standard doses of 60-mg fimasartan, 80-mg valsartan, and 10-mg olmesartan were administered for 2 weeks, then forcibly up-titrated higher doses (fimasartan 120 mg, valsartan 160 mg, olmesartan 20 mg) were given for 4 weeks. ABP was measured before and after the 6-week treatment. Primary endpoint was reduction of sitting office systolic BP (SiSBP) of fimasartan compared to valsartan after 6 weeks. Secondary endpoints were reduction of sitting office diastolic BP (SiDBP) and 24 hrs, day-time, and night-time mean systolic and diastolic ABP (ASBP, ADBP) after 6 weeks.Results: Patients&rsquo; mean age was 58.34+- 7.68 years, and 289 patients were male (79.18%). After the 6-week treatment, SiSBP reduction of fimasartan and valsartan were - 16.26+- 15.07 and - 12.81+- 13.87 (p=0.0298) and SiDBP were - 7.63+- 9.67 and - 5.14+- 8.52 (p=0.0211). Reductions in 24 hrs mean ASBP were - 15.22+- 13.33 and - 9.45+- 12.37 (p=0.0009), and ADBPs were - 8.74+- 7.55 and - 5.98+- 7.85 (p=0.0140). Reductions of night-time ASBPs were - 16.80+- 15.81 and - 10.32+- 14.88 (p=0.0012), and those of night-time ADBPs were - 8.89+- 9.93 and - 5.55+- 9.70 (p=0.0152). Reduction of BP in olmesartan group did not demonstrate significant difference with fimasartan group in all end-points.Conclusion: Fimasartan 120-mg treatment demonstrated superior efficacy in reduction of SiSBP, SiDBP, and 24 hrs ASBP and ADBP compared to valsartan 160 mg. Reduction of night-time ASBP from baseline was largest in fimasartan group, suggesting that fimasartan may be effective for recovering dipping pattern.NCT number: NCT02495324 (Fimasartan Achieving SBP Target (FAST) study).Keywords: 24 hr ambulatory blood pressure monitoring, angiotensin receptor blocker, essential hypertension, antihypertensive</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">24-hour ambulatory blood pressure monitoring</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">angiotensin receptor blocker</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">essential hypertension</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antihypertensive</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ihm SH</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jang SW</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Her SH</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Park CS</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lee JM</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chang K</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jeon DS</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yoo KD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Seung KB</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Drug Design, Development and Therapy</subfield><subfield code="d">Dove Medical Press, 2008</subfield><subfield code="g">(2020), Seite 347-360</subfield><subfield code="w">(DE-627)578533138</subfield><subfield code="w">(DE-600)2451346-5</subfield><subfield code="x">11778881</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2020</subfield><subfield code="g">pages:347-360</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/618dc4eeae68416fab8102190bd2926f</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/effect-of-fimasartan-versus-valsartan-and-olmesartan-on-office-and-amb-peer-reviewed-article-DDDT</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1177-8881</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2020</subfield><subfield code="h">347-360</subfield></datafield></record></collection>
|
| score |
7.4027376 |